Stay updated on Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Sign up to get notified when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.

Latest updates to the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page
- CheckyesterdayChange DetectedThe latest version adds a Study Status entry and Revision: v3.3.3 dated 2025-12-17. The previous HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed on 2025-06-10.SummaryDifference0.5%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedFooter revision label updated to v3.3.2; the previous v3.2.0 label was removed.SummaryDifference0.1%

- Check36 days agoChange DetectedThe notice about government funding and operating status was removed from the page in the latest version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check58 days agoChange DetectedNew screenshot shows minor UI/layout updates to the header area and the study table presentation on the history page. The underlying content and historical records remain the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference11%

- Check87 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release.SummaryDifference0.3%

Stay in the know with updates to Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.